Opin season arrives for patients as AI drives Opyl boom in Q2 receipts

Aussie startup Opyl had another strong December quarter – customer registrations have almost doubled as demand for its AI-powered clinical trial recruitment platform, Opin, grows.

“Opin’s value is accelerating each quarter as the R&D and Operations teams move closer together and work on Opin advances at a faster pace.” – CEO Michelle Gallaher – as featured in a Stockhead article.

Read the full version here.